

ASX Market Announcement

Appendix 4C and Quarterly Activities Report – March 2025

Sydney Australia, 30 March, 2026: Genetic Technologies Limited (ASX: GTG, “Company”, “GTG”) refers to its Appendix 4C and Quarterly Activities Report for the quarter ended 31 March 2025 as set below.

Voluntary Administration and Deed of Company Arrangement

On 20 November 2024, the Directors of Genetic Technologies Limited appointed Ross Blakeley and Paul Harlond of FTI Consulting as Joint and Several Voluntary Administrators (Administrators) pursuant to section 436A of the Corporations Act 2001.

During the quarter ended 31 March 2025, the Company remained subject to external administration while the Administrators progressed the sale and recapitalisation process.

At the second meeting of creditors held on 27 February 2025, creditors resolved that the Company enter into a Deed of Company Arrangement (DOCA). The DOCA was subsequently executed on 19 March 2025, with the Administrators continuing as Deed Administrators. The Deed Administrators have continued to progress the implementation of the DOCA and the proposed recapitalisation of the Company.

Sale of geneType Business

As previously announced, on 23 December 2024, the Company completed the sale of its geneType business and assets to Rhythm Biosciences Limited for \$625,000 plus GST, inclusive of Rhythm agreeing to pay select creditors and assume statutory employee entitlements for transferring Australian employees.

The sale included the Group’s intellectual property associated with the geneType business, licences and permits, research assets, customer and supply chain contracts and certain office assets.

During the March quarter, the Company received \$510,000 in proceeds from the disposal of businesses, reflected in the investing cash flows for the quarter.

For personal use only

ASX Market Announcement

Financial and Cashflow Overview

At the end of March 2025, the Company had \$0.27 million in cash and cash equivalents.

Cash receipts from customers for the quarter of \$0.485 million were \$1.135 million lower than the prior quarter. The business was not trading during this period. All cashflows received were residual in nature, arising from the administration process, and do not represent operational trading activity.

Net cash flow from all activities during the quarter were a net outflow of \$0.73 million, with net outflows from operating activities of \$1.241 million partially offset by net cash inflows from investing activities of \$0.51 million from net proceeds from sale of business and assets.

Related Party Payments

In accordance with ASX Listing Rule 4.7C.3, payments to related parties and their associates outlined in the Company's Appendix 4C for the quarter ended 31 March 2025 were nil. This has been disclosed in Section 6.1 of the attached Appendix 4C.

– END –

Authorised for release by the Board of Directors.

For personal use only

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Genetic Technologies Limited

ABN

72 088 749 008

Quarter ended ("current quarter")

31-Mar-25

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	485	3,940
1.2 Payments for		
(a) research and development	-	(103)
(b) product manufacturing and operating costs	(204)	(1,810)
(c) advertising and marketing	(46)	(347)
(d) leased assets	(14)	(175)
(e) staff costs	(288)	(2,601)
(f) administration and corporate costs	(1,181)	(2,223)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	7	20
1.5 Interest and other costs of finance paid	-	(86)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	1,839
1.8 Other (provide details if material)	-	
1.9 Net cash from / (used in) operating activities	(1,241)	(1,546)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	(7)
(d) investments	-	-
(e) intellectual property	-	-

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
(f) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) entities	-	-
(b) businesses	510	924
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	510	917

3. Cash flows from financing activities		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	-	38
3.2 Proceeds from issue of convertible debt securities	-	-
3.3 Proceeds from exercise of options	-	-
3.4 Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5 Proceeds from borrowings	-	156
3.6 Repayment of borrowings	-	(300)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	0	(106)

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of period	1,012	1,021
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(1,241)	(1,546)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	510	917

For personal use only

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	0	(106)
4.5	Effect of movement in exchange rates on cash held	(11)	(16)
4.6	Cash and cash equivalents at end of period	270	270

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	270	1,013
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	270	1,013

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	-
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<p><i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i></p>		

For personal use only

7. Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i>		
<i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	0	0
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
N/A		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(1,241)
8.2 Cash and cash equivalents at quarter end (item 4.6)	270
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	270
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	0.22
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: **30 March 2026**

Authorised by: **Board of Directors**
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.